PD-1 Silent PSMA or PSCA Targeted CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PD-1 Silent PSMA or PSCA Targeted CAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PD-1 Silent PSMA or PSCA Targeted CAR-T overview
The therapeutic candidate is under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It comprises of autologous T cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing prostate specific membrane antigen (PSMA) or prostate stem cell antigen (PSCA). It is administered through parenteral route.
Shanghai Unicar-Therapy Bio-Medicine Technology overview
Shanghai Unicar-Therapy Bio-Medicine Technology., is a pharmaceutical company and a tumor immunotherapy technology developer. The company is headquartered China.
For a complete picture of PD-1 Silent PSMA or PSCA Targeted CAR-T’s drug-specific PTSR and LoA scores, buy the report here.